43. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D: HIV-1 Nef protein protects infected main cells against killing by cytotoxic T lymphocytes. Nature 1998, 391:397?01. 44. Dikeakos JD, Thomas L, Kwon G, Elferich J, Shinde U, Thomas G: An interdomain binding website on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I. Mol Biol Cell 2012, 23:2184?197. 45. Emert-Sedlak LA, Narute P, Shu ST, Poe JA, Shi H, Yanamala N, Alvarado JJ, Lazo JS, Yeh JI, Johnston PA, Smithgall TE: Effector Kinase Coupling Enables High-Throughput Screens for Direct HIV-1 Nef Antagonists with Antiretroviral Activity. Chem Biol 2013, 20:82?1. 46. Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, De Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC: 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship research toward the discovery of N-(2-chloro-6-methylphenyl)-2[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.Buy2227206-09-7 J Med Chem 2006, 49:6819?832. 47. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, Ishimori M, Nagai H, Li YF, Yura T, Bacon KB: The orally obtainable spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin5-ylamino]nicotinamide dihydrochloride (BAY 61?606) blocks antigeninduced airway inflammation in rodents. J Pharmacol Exp Ther 2003, 306:1174?181. 48. Trott O, Olson AJ: AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, effective optimization, and multithreading. J Comput Chem 2010, 31:455?61. 49. Liu LX, Heveker N, Fackler OT, Arold S, Le Gall S, Janvier K, Peterlin BM, Dumas C, Schwartz O, Benichou S, Benarous R: Mutation of a conserved residue (D123) needed for oligomerization of human immunodeficiency virus sort 1 Nef protein abolishes interaction with human thioesterase and final results in impairment of Nef biological functions. J Virol 2000, 74:5310?319. 50. Jia X, Singh R, Homann S, Yang H, Guatelli J, Xiong Y: Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef. Nat Struct Mol Biol 2012, 19:701?06. 51. Niesen FH, Berglund H, Vedadi M: The use of differential scanning fluorimetry to detect ligand interactions that market protein stability. Nat Protoc 2007, 2:2212?221. 52. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ Jr, Wasney GA, Yeung R, Arrowsmith C, Ball LJ, Berglund H, Hui R, Marsden BD, Nordlund P, Sundstrom M, Weigelt J, Edwards AM: Chemical screening strategies to identify ligands that market protein stability, protein crystallization, and structure determination.N1,N1-Diphenylbenzene-1,4-diamine uses Proc Natl Acad Sci U S A 2006, 103:15835?5840.PMID:33734019 53. Smithgall TE, Thomas G: Compact molecule inhibitors on the HIV-1 virulence aspect, Nef. Drug Discov Currently: Technol 2013, ten:e523 529. 54. Lugari A, Breuer S, Coursindel T, Opi S, Restouin A, Shi X, Nazabal A, Torbett BE, Martinez J, Collette Y, Parrot I, Arold ST, Morelli X: A certain protein disorder catalyzer of HIV-1 Nef. Bioorg Med Chem 2011, 19:7401?406. 55. Betzi S, Restouin A, Opi S, Arold ST, Parrot I, Guerlesquin F, Morelli X, Collette Y: Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application towards the HIV-1 Nef protein. Proc Natl Acad Sci U S A 2007, 104:19256?9261. 56. Gervaix A,.
